MOREPENLAB vs PPLPHARMA: Stock Comparison
PIRAMAL PHARMA is the larger company by market capitalisation. MOREPEN LAB. shows a higher ROE, faster revenue growth and lower leverage, while PIRAMAL PHARMA shows a lower P/E. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
MOREPENLAB leads 8; PPLPHARMA leads 4 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | MOREPENLAB | PPLPHARMA |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | MOREPENLAB | PPLPHARMA |
|---|---|---|
| Live Price | ₹115.78 | ₹211.35 |
| Day Change | 0.43% | -0.54% |
| Volume | 1.53 Cr | 34.09 L |
| 52-Week High | ₹122.55 | ₹231.93 |
| 52-Week Low | ₹33.05 | ₹132.3 |
| Distance from 52W High | -5.52% | -8.87% |
Valuation
| Metric | MOREPENLAB | PPLPHARMA |
|---|---|---|
| Market Cap | ₹6,343 Cr | ₹28,211 Cr |
| P/E Ratio | 45.21x | 0x |
| P/B Ratio | 5.09x | 3.45x |
| EPS | ₹1.03 | ₹0.85 |
| Book Value | ₹22.76 | ₹61.31 |
| Dividend Yield | 0% | 0% |
Growth
| Metric | MOREPENLAB | PPLPHARMA |
|---|---|---|
| Revenue Growth (TTM YoY) | 4% | -0.1% |
| EPS Growth (TTM YoY) | -18.9% | 0% |
| Qtr Sales Growth | 5.38% | -50.44% |
| Qtr Profit Growth | 4.45% | 263.54% |
Profitability & Leverage
| Metric | MOREPENLAB | PPLPHARMA |
|---|---|---|
| ROE | 7.61% | -3.99% |
| ROCE | 6.52% | 0.86% |
| Net Margin | 5.25% | -3.68% |
| Operating Margin | 7.55% | 1.21% |
| Debt to Equity | 0.16x | 0.67x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | MOREPENLAB | PPLPHARMA |
|---|---|---|
| Promoter Holding | 35.65% | 34.8%▼ 0.06 pp |
| FII Holding | 1.46%▼ 0.12 pp | 12.52%▼ 17.66 pp |
| DII Holding | 1.28%▲ 0.03 pp | 14.57%▼ 1.04 pp |
| Public Holding | 61.59%▲ 0.09 pp | 37.63%▲ 18.62 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: MOREPEN LAB. and PIRAMAL PHARMA.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.